KRASG12D inhibition in pancreatic cancer: Fas expression facilitates immune clearance
- PMID: 37699334
- DOI: 10.1016/j.devcel.2023.08.020
KRASG12D inhibition in pancreatic cancer: Fas expression facilitates immune clearance
Abstract
In an article in this issue of Developmental Cell and in a second paper in Cancer Cell, Mahadevan et al. demonstrate that KrasG12D suppression remodels the immunosuppressive microenvironment of KrasG12D pancreatic cancers, recruits activated CD8+ cytotoxic T cells, and epigenetically upregulates Fas expression in cancer cells, leading to tumor clearance via Fas/FasL-mediated apoptosis.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.Y. declares no competing interests. W.P. is a consultant for Astellas, EXACT Therapeutics AS, American Physician Institute, Curio Science, TEMPUS, and Integrity Continuing Education and receives research funding to his institution from Merck, Astellas, and Miracogen. R.Y. is a consultant for Mirati Therapeutics and Amgen (unpaid), has received speaker’s honorarium from Zai Lab, and receives research funding to her institution from Mirati Therapeutics, Pfizer, Boehringer Ingelheim, and Daiichi Sankyo.
Comment on
-
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells.Dev Cell. 2023 Sep 11;58(17):1562-1577.e8. doi: 10.1016/j.devcel.2023.07.025. Epub 2023 Aug 24. Dev Cell. 2023. PMID: 37625403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
